Corcept Therapeutics to Present at Upcoming Investor Conferences

Corcept Therapeutics (NASDAQ: CORT) will present at two upcoming investor conferences.

Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) will present at two upcoming investor conferences. The Jefferies London Healthcare Conference is on November 16, 2021, at 5:00 pm GMT, featuring a fireside chat format. The Evercore ISI 4th Annual HealthCONx Conference is scheduled for November 30, 2021, at 11:20 am EST, also in a fireside chat format.

Corcept specializes in developing drugs for serious metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol. Its product Korlym® is FDA-approved for Cushing’s syndrome, supported by a robust portfolio of proprietary cortisol modulators.

Argus Session date unavailable

-2.83% session move Open Argus

Details

News Market Reaction – CORT

The recorded move for CORT in the trading session of this news was -2.83%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced that the company will present at the following investor conferences:

Jefferies London Healthcare Conference

• Date: Tuesday, November 16, 2021
• Presentation Time: 5:00 pm GMT
• Format: Fireside Chat
  

Evercore ISI 4^th Annual HealthCONx Conference

• Date: Tuesday, November 30, 2021
• Presentation Time: 11:20 am EST
• Format: Fireside Chat
  

About Corcept Therapeutics
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dates will Corcept Therapeutics present at investor conferences?

Corcept Therapeutics will present on November 16, 2021, at the Jefferies London Healthcare Conference, and on November 30, 2021, at the Evercore ISI 4th Annual HealthCONx Conference.

What is the presentation format for Corcept's upcoming conferences?

Both presentations will be in a fireside chat format.

What is the significance of Korlym® by Corcept?

Korlym® is the first drug approved by the FDA for treating Cushing’s syndrome, highlighting Corcept's focus on cortisol modulation.

What disorders does Corcept Therapeutics focus on?

Corcept Therapeutics focuses on severe metabolic, oncologic, and neuropsychiatric disorders through cortisol modulation.

What is the stock symbol for Corcept Therapeutics?

The stock symbol for Corcept Therapeutics is CORT.